92 related articles for article (PubMed ID: 25375151)
1. Prognostic role of ERCC1 in advanced non-small-cell lung cancer: a systematic review and meta-analysis.
Roth JA; Carlson JJ
Clin Lung Cancer; 2011 Nov; 12(6):393-401. PubMed ID: 21723790
[TBL] [Abstract][Full Text] [Related]
2. Expression Levels of DNA Damage Repair Proteins Are Associated With Overall Survival in Platinum-Treated Advanced Urothelial Carcinoma.
Mullane SA; Werner L; Guancial EA; Lis RT; Stack EC; Loda M; Kantoff PW; Choueiri TK; Rosenberg J; Bellmunt J
Clin Genitourin Cancer; 2016 Aug; 14(4):352-9. PubMed ID: 26778300
[TBL] [Abstract][Full Text] [Related]
3. Application of postoperative adjuvant radiotherapy in limited-stage small cell lung cancer: A systematic review and meta-analysis.
Zhang C; Zhao G; Wu H; Jiang J; Duan W; Fan Z; Wang Z; Wang R
Radiother Oncol; 2024 Apr; 193():110123. PubMed ID: 38309584
[TBL] [Abstract][Full Text] [Related]
4. Duration of chemotherapy for small cell lung cancer: a meta-analysis.
Zhou H; Zeng C; Wei Y; Zhou J; Yao W
PLoS One; 2013; 8(8):e73805. PubMed ID: 24023692
[TBL] [Abstract][Full Text] [Related]
5. Role of rs873601 Polymorphisms in Prognosis of Lung Cancer Patients Treated with Platinum-Based Chemotherapy.
Zou T; Liu JY; Qin Q; Guo J; Zhou WZ; Li XP; Zhou HH; Chen J; Liu ZQ
Biomedicines; 2023 Nov; 11(12):. PubMed ID: 38137354
[TBL] [Abstract][Full Text] [Related]
6. Association between chemotherapy-induced myelosuppression and curative efficacy of 2-cycle chemotherapy in small cell lung cancer.
Wang X; Gu S; Wen J; Zhang L; Qi X
Cancer Chemother Pharmacol; 2024 Feb; 93(2):151-159. PubMed ID: 37926753
[TBL] [Abstract][Full Text] [Related]
7. Heterogeneity of excision repair cross-complementation group 1 gene expression in non-small-cell lung cancer patients.
Smirnov S; Pashkevich A; Liundysheva V; Babenko A; Smolyakova R
Mol Clin Oncol; 2015 Jan; 3(1):227-331. PubMed ID: 25469300
[TBL] [Abstract][Full Text] [Related]
8. Genotyping, in silico screening and molecular dynamics simulation of SNPs of MGMT and ERCC1 gene in lung cancer patients treated with platinum-based doublet chemotherapy.
Singh S; Gupta A; Singh N; Sengupta PS; Panda SK; Sharma S
J Biomol Struct Dyn; 2023 Sep; ():1-20. PubMed ID: 37771161
[TBL] [Abstract][Full Text] [Related]
9. Mutations in the DNA polymerase binding pathway affect the immune microenvironment of patients with small-cell lung cancer and enhance the efficacy of platinum-based chemotherapy.
Lin A; Mou W; Zhu L; Yang T; Zhou C; Zhang J; Luo P
Cancer Innov; 2023 Dec; 2(6):500-512. PubMed ID: 38125769
[TBL] [Abstract][Full Text] [Related]
10. Gene expression markers in peripheral blood and outcome in patients with platinum-resistant ovarian cancer: A study of the European GANNET53 consortium.
Obermayr E; Mohr T; Schuster E; Braicu EI; Taube E; Sehouli J; Vergote I; Pujade-Lauraine E; Ray-Coquard I; Harter P; Wimberger P; Joly-Lobbedez F; Mahner S; Moll UM; Concin N; Zeillinger R
Int J Cancer; 2024 Apr; ():. PubMed ID: 38676430
[TBL] [Abstract][Full Text] [Related]
11. Methodological quality evaluation of systematic reviews or meta-analyses on ERCC1 in non-small cell lung cancer: a systematic review.
Tao H; Zhang Y; Li Q; Chen J
J Cancer Res Clin Oncol; 2017 Nov; 143(11):2245-2256. PubMed ID: 28875225
[TBL] [Abstract][Full Text] [Related]
12. Excision Repair Cross-complementation Group 1 is a Prognostic Biomarker in Patients with Colorectal Cancer Receiving Chemotherapy.
Li MX; Bi XY; Zhao H; Huang Z; Han Y; Zhao DB; Zhao JJ; Cai JQ
Chin Med J (Engl); 2016 Mar; 129(5):586-93. PubMed ID: 26904994
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of ERCC1 and ERCC2 gene polymorphisms in patients with gastric cancer receiving platinum-based chemotherapy.
Mo J; Luo M; Cui J; Zhou S
Int J Clin Exp Pathol; 2015; 8(11):15065-71. PubMed ID: 26823845
[TBL] [Abstract][Full Text] [Related]
14. The prognostic value of excision repair cross-complementation group 1 (ERCC1) in patients with small cell lung cancer (SCLC) receiving platinum-based chemotherapy: evidence from meta-analysis.
Yang Y; Luo X; Yang N; Feng R; Xian L
PLoS One; 2014; 9(11):e111651. PubMed ID: 25375151
[TBL] [Abstract][Full Text] [Related]
15. Association of ERCC1-C118T and -C8092A polymorphisms with lung cancer risk and survival of advanced-stage non-small cell lung cancer patients receiving platinum-based chemotherapy: a pooled analysis based on 39 reports.
Xu TP; Shen H; Liu LX; Shu YQ
Gene; 2013 Sep; 526(2):265-74. PubMed ID: 23727606
[TBL] [Abstract][Full Text] [Related]
16. The prognostic and predictive value of excision repair cross-complementation group 1 (ERCC1) protein in 1288 patients with head and neck squamous cell carcinoma treated with platinum-based therapy: a meta-analysis.
Bišof V; Zajc Petranović M; Rakušić Z; Samardžić KR; Juretić A
Eur Arch Otorhinolaryngol; 2016 Sep; 273(9):2305-17. PubMed ID: 26179868
[TBL] [Abstract][Full Text] [Related]
17. Impact of ERCC1 expression on treatment outcome in small-cell lung cancer patients treated with platinum-based chemotherapy.
Sodja E; Knez L; Kern I; Ovčariček T; Sadikov A; Cufer T
Eur J Cancer; 2012 Dec; 48(18):3378-85. PubMed ID: 22795264
[TBL] [Abstract][Full Text] [Related]
18. ERCC1 expression levels predict the outcome of platinum-based chemotherapies in advanced bladder cancer: a meta-analysis.
Li S; Wu J; Chen Y; Tang W; Peng Q; Deng Y; Xie L; Wang J; Huang S; Li R; Qin X; Zhao J
Anticancer Drugs; 2014 Jan; 25(1):106-14. PubMed ID: 24025563
[TBL] [Abstract][Full Text] [Related]
19. The association between the ERCC1/2 polymorphisms and the clinical outcomes of the platinum-based chemotherapy in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis.
Yang Y; Xian L
Tumour Biol; 2014 Apr; 35(4):2905-21. PubMed ID: 24338713
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
